Biomarker

Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help...

Protease and serpin activity affect the gut barrier, immunity, and microbial ecology—processes central to IBD. Integrating these pathways could help identify biomarkers or targets that explain why IBD varies between...

Treatment resistance is a major hurdle in IBD care; this review maps how microbiota, immune imbalance, and epigenetics may work together to cause drug-resistant disease and suggests potential precision strategies that...

This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.

Researchers are investigating circRNAs as potential biomarkers and therapeutic targets in IBD because they may help explain disease mechanisms and lead to better diagnostics or treatments in the future.

The study identifies distinct fecal bile acid signatures in CRC versus UC that might help develop noninvasive tests to distinguish malignancy from chronic inflammatory disease of the colon.

The study provides a more rigorous, leakage-free machine-learning analysis of a major IBD microbiome cohort and proposes reproducible microbial and metabolic pathway candidates that could eventually help IBD diagnosis or...

Distinguishing acute infectious gastroenteritis from new‑onset IBD can be clinically challenging. Faecal biomarkers that help tell these apart could speed correct diagnosis and treatment and avoid unnecessary...

Patients with UC who appear healed on endoscopy can still relapse; a biopsy-based model could help separate lower- and higher-risk patients and guide monitoring or research enrollment.

FABP2 is presented as a sensitive biomarker of intestinal mucosal injury and a possible contributor to IBD mechanisms; if validated, it could improve disease monitoring and suggest new therapeutic targets.

Researchers identified molecular features of a proposed “ferro‑aging” state in UC and nominated CHST15 and MSN as biomarkers, which could help understand disease biology and point to new experimental targets for therapy...

The review summarizes how extracellular vesicles (EVs) shape immune responses and barrier repair in the gut and discusses their potential as accessible biomarkers and as vehicles for precise IBD therapies — topics that...

A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...

The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...

This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...

If you have overweight or obesity, this study suggests measurable blood proteins linked to inflammation may be associated with higher future risk of ulcerative colitis. Identifying such markers could help research on...

A strategic, pediatric-focused research agenda helps target studies where children with IBD and related conditions most need better diagnostics, biomarkers, and treatments. Prioritizing multi-center registries and...

Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...

Researchers are exploring ferroptosis as a double-edged mechanism: preventing it may protect healthy gut lining in IBD, while inducing it might help treat colorectal cancer. Advances could lead to new biomarkers or...

Non-invasive biomarkers can help detect and monitor IBD activity, distinguish IBD from other GI conditions, and potentially predict relapse—tools that may reduce need for invasive tests.

Researchers present a small platelet-related gene signature (TRIM22, TIMP1, RAC2) that may help understand UC biology and point toward blood-based biomarkers. If validated further, such markers might aid noninvasive...

Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...

Fucosylation appears to influence intestinal barrier function, host–microbiota interactions, and immune responses — processes central to IBD pathogenesis. If validated, fucosylation-related biomarkers or therapies could...

Basal crypt dysplasia is easy to miss but linked to higher risk of advanced colorectal neoplasia in longstanding IBD. Improved recognition and use of p53 immunohistochemistry or complementary biomarkers could affect...

TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...

If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...

Treg/Th17 balance is a central immune mechanism implicated in IBD pathogenesis; understanding how microbes, metabolites, and tissue context control that balance could inform new biomarkers and targeted therapies.

This review summarizes human evidence that pesticides in the diet could affect the gut microbiome and may be linked to gastrointestinal outcomes including IBD; strongest consistent signals were for organochlorine...

Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...

IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...

The paper identifies a gut microbiome–driven pathway (flagellin → TLR5 → IL-15 → ARA) that might link intestinal microbial changes to systemic inflammation seen in long COVID and other immune-mediated diseases,...

If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.

Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...

The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...

A blood test that more reliably distinguishes UC from CD could reduce diagnostic uncertainty and help guide appropriate long‑term management for people with colonic inflammatory bowel disease.

The paper suggests a new molecular link—low ALIX expression—to inflammatory cell death (pyroptosis) that might help explain mucosal inflammation in ulcerative colitis. If validated, that pathway could point to biomarkers...

If validated, blood protein signatures that appear years before symptoms could help identify people at higher risk of Crohn’s disease and point to lifestyle or dietary measures that alter early biology.

People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...

This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...

The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...

Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.

This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.

IBD increases risk of osteoporosis; identifying blood proteins that predict later bone loss could help flag higher-risk patients and reveal biological links between gut inflammation and bone health.

Many people with IBD try dietary changes to manage symptoms. This review summarizes what published adult studies report and points toward whole-food and Mediterranean-style patterns as commonly supported approaches.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Infliximab. The original article is from Journal of Genetic Engineering and...

Understanding how the gut virome shapes regulatory T cells could reveal new biomarkers or therapeutic targets for IBD and related systemic immune diseases. This may help explain unexplained flares or individual...

Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.